A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Inclusion Criteria: * Patients with a histologic or cytologic diagnosis of intrahepatic cholangiocarcinoma with stage IV; * Have progressed after systematic chemotherapy/target therapy, or cannot tolerated with first-line treatment; * The previous treatment and the present trial registration must be at least 2 weeks apart, and they must have recovered from any toxicity of a previous treatment; * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1; * Eastern Cooperative Oncology Group performance score (ECOG): 0-2; * Life expectancy of at least 12 weeks; * Subjects who understand and voluntarily signed a written informed consent form. Exclusion Criteria: * Previous locoregional therapy within 4 weeks prior to enrollment. * Diagnosed with hepatocellular carcinoma, mixed cell carcinoma and fibrolamellar hepatocellular carcinoma. * History of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma. * Prepared for liver transplantation. * Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, within 30 days after major surgery, uncontrolled high blood pressure medication, III-IV level cardiac insufficiency, severe liver and kidney dysfunction). * A previous history of Interstitial pulmonary disease, drug-induced interstitial disease, radiation pneumonitis requiring hormonal therapy or active interstitial lung disease with any clinical evidence. * Use of CYP3A4 inhibitor within 7 days or CYP3A4 inducer within 12 days prior to enrollment. * Patients with central nervous system metastases or brain metastasis * Previous definite diagnosis of neuropsychiatric disturbances, including epilepsy or dementia. * Pregnant or lactating women. * Patients with bone metastasis received palliative radiation within 4 weeks prior to enrollment.